Pharma Partnerships Vital in Stagnant Alzheimer’s Disease Treatment Market, says GlobalData Analyst
23 September 2014 | By GlobalData
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData...